EVALUATION OF THE NOCEBO EFFECT OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE SWITCHED THE ADMINISTRATION ROUT FROM THE ENDOVENOUS ABATACEPT TO SUBCUTANEOUS